Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].

Medicina clinica - 10 Jun 1995

Cervantes F, Miller J S, McGlave P B

Abstract excerpt

BACKGROUND: Recent studies indicate that patients with chronic myeloid leukemia (CML) have a population of benign cytolytic cells (natural killer or NK) in their peripheral blood which may expand and activate in vitro in the presence of interleukin-2 (IL-2) leading to cytolytic cells activated by lymphokine or LAK cells (lymphokine-activated killer). METHODS: Thirteen patients with CML in the chronic phase of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Centrifugation, Density Gradient
Share to Cytotoxicity Tests, Immunologic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Killer Cells, Lymphokine-Activated

Share to Killer Cells, Natural

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Lymphocyte Subsets

Share to Phenotype

Source

Identifiers

PMID: 7603094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].PMID 7603094Read ↗

Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-alpha-treated chronic myelogenous leukaemia patients.Semantic proximity Read ↗

Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia.Semantic proximity Read ↗

Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.Semantic proximity Read ↗

Immunologic and clinical aspects of natural killer cells in human leukemia.Semantic proximity Read ↗

Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.Semantic proximity Read ↗

Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia.Semantic proximity Read ↗

Lysis of human alveolar macrophages by lymphokine-activated killer cells.Semantic proximity Read ↗

[Phenotypic and functional study of natural killer lymphocytes in flow cytometry: application to renal transplantation].Semantic proximity Read ↗

High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.Semantic proximity Read ↗

Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.Semantic proximity Read ↗

NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.